Imagion Biosystems Ltd. (AU:IBX) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Imagion Biosystems Ltd. is set to boost its MagSense® molecular MRI imaging technology, supported by a $3 million capital raise. The funds will advance clinical development, including a Phase 2 study for its HER2 imaging agent, and extend its technology to prostate and ovarian cancer detection. The company also welcomes Dr. Susan Harvey as a new Medical Affairs Advisor, enhancing its expertise in cancer imaging.
For further insights into AU:IBX stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue